CJ Bioscience, Inc.
Research CJ Bioscience, Inc. (311690.KQ) on Bullrun: market cap KRW 48.34B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker311690.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 48.34B
- Financial periodQ2 2026
- RevenueKRW 898.15M
- Net income-KRW 6.21B
- Free cash flow-KRW 3.71B
- Gross margin23.6%
Valuation Snapshot
latest market cap is KRW 48.34B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 48.34B | n/a | n/a | n/a |
Dividend history
About CJ Bioscience, Inc.
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CJ Bioscience, Inc.'s market cap?
CJ Bioscience, Inc.'s market capitalization is KRW 48.34B.
What does CJ Bioscience, Inc. do?
CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma.